Sirona Biochem to Exhibit at PCHi 2019 in Guanzhou China
Momentum Public Relations
Press Release: February 26, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that it will exhibit at The Personal Care and Homecare Ingredients trade show (PCHi 2019) in Guanzhou China Feb 26-28th 2019. The PCHi 2019 trade show is China’s #1 sourcing platform for the global personal care industry https://www.pchi-china.com/en/. Sirona will be principally promoting its novel skin lightening agent TFC-1067 in addition to its anti-wrinkle and anti-aging compounds.
Sirona’s business development team in China, will be supported by a large Chinese cosmetic distribution company. The distribution company is working closely with Sirona through a memorandum of understanding to establish an optimal pathway to commercialize TFC-1067 into the Chinese skin lightening market. The PCHi 2019 will introduce Sirona’s technology to an estimated 75 cosmetic companies and numerous market experts. The business development team assembled has local knowledge and expertise that allows Sirona to navigate this immense opportunity.
Thanks to the efforts of PRC Partners Limited, Sirona has established a strong and experienced team with the diverse skill to navigate the optimal pathways to commercialize into this market. The global skin lightening market is estimated to grow to US$31.2 billion by 20241. Asia makes up the largest and fastest growing segment of the market.
Sirona would also like to thank the strong support for our recently announced financing which has been filed with the TSX Venture exchange. The Offering is subject to TSX Venture Exchange (“TSXV“) final acceptance of requisite regulatory filings. When approved by the TSXV, a news release will be issued by the company.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona Biochem Receives Up-front Payment for Right of First Refusal Contract for Skin Lightener TFC-1067
Momentum Public Relations
Press Release: February 06, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announces that it has signed a Right of First Refusal (ROFR) agreement with an industry-leading, skincare company to license Sirona’s skin lightener, TFC-1067. The company is a leader in North American skincare sales with rapidly growing international sales channels.
The skincare company has completed extensive due diligence on TFC-1067. This includes both the data package provided by Sirona as well as their independent research and analysis on the compound. This work is contributing to the goal of an international commercial launch of what we are proving will be both a safe and effective skin lightener in an industry where other compounds typically suffer from either poor efficacy or toxicity issues.
The ROFR agreement, which includes all territories except China, states that upon receipt of the clinical trial report from dermatologist Dr. Zoe Draelos, the company will have 30 days to review the data. At that time, the company will notify Sirona of their intent to conclude a licensing agreement. At their request, the company’s identity and the detailed agreement will remain confidential until a definitive agreement is executed.
Sirona has received an up-front payment for the acceptance of the ROFR.
“We are very pleased to have established this arrangement. A great deal of time and resources have been invested by both Sirona and the skincare company working on the advancement of TFC-1067 with the goal of an international commercial launch”, reports Dr. Howard Verrico, CEO of Sirona. “In order to protect the company and justify their ongoing efforts, the ROFR was a necessary step in advance of our clinical trial results, as these results are also greatly anticipated by other major skincare companies. This is an exciting time for Sirona’s team here in Canada as well as our scientific team in France and marks another milestone towards commercially launching a disruptive new skin lightening ingredient in this 20 Billion USD global skin lightening market1.”
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
1 |
Fact.MR (July 2018) Retrieved from: https://globenewswire.com/news-release/2018/07/10/1535161/0/en/Key-Insights-on-Skin-Lightening-Products-Market-through-2022-by-Fact-MR.html |
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2019/06/c8940.html
Contact:
regarding this press release, please contact: Christopher Hopton, CFO, Sirona Biochem Corp., Phone: 1.604.282.6064, Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona Biochem’s SGLT2 Inhibitor in Testing for Animal Health
Momentum Public Relations
Press Release: December 11, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) announced today that testing has commenced for the SGLT2 inhibitor, TFC-039, in cats.
Several months ago, Sirona was approached by a company to test TFC-039 as a drug for treating diabetes in cats and dogs. The company requested to remain confidential.
A proof of concept study has begun to evaluate the glucosuria effect of TFC-039. This will address the simple question of whether the molecule engages with the feline receptor in a manner that would make TFC-039 a suitable drug development candidate. Results for this initial study are expected later this month.
“We are excited about the prospect of our SGLT-2 inhibitor being used in not only another market outside of China, but in other species as well,” said CEO Dr. Howard Verrico. “The upside to developing a drug for animals includes faster approval, less competition with generics and longer product life. The global pet healthcare market is projected to reach 65 billion USD by 2025. Diabetes is a common illness in pets, particularly in felines. This is attributed in part due to increasing pet ownership, increasing obesity rates, and improved rates of diagnosis. There is also a growing trend to treat the pets suffering from this illness to allow them to live near normal lifespans.”
If successful, the company’s primary focus would be to create the drug for the North American and European markets, followed by Japan and Australia. The market continues to grow, at roughly 5%. Sirona is looking forward to continuing the collaboration with this company.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Begins Proof of Efficacy Clinical Trial for TFC-1067
Momentum Public Relations
Press Release: November 6, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company“) reported today the successful launch of the clinical trial for skin-lightener TFC-1067 with leading dermatologist Dr. Zoe Draelos.
In September, Sirona reported that the Company was awaiting final results from the second clinical trial for the Human Repeat Insult Patch Test (HRIPT). This test was performed on 110 people to assess safety of TFC-1067. The data confirmed TFC-1067 as a non-sensitizer, providing the final support needed for toxicologist approval.
Following completion of the preliminary studies and toxicologist approval, the Company has begun the enrollment process for the clinical trial. All material, including the formulated TFC-1067 cream, has been delivered to the clinical-trial center in North Carolina and final International Review Board approval is pending.
Once patients have been enrolled, the twelve-week assessment of TFC-1067 will begin under the supervision of Dr. Draelos, who has conducted clinical trials for many top pharmaceutical companies worldwide. The Company looks forward to using the results to further and solidify discussions with partners in North America and Asia, as final confirmation of TFC-1067’s safety and efficacy as a skin-lightening agent.
“This clinical trial marks a major milestone for Sirona Biochem and its scientific team,” said Dr. Howard Verrico. “With the anticipated start of the clinical trial for Sirona’s SGLT-2 inhibitor, TFC-039, by partner Wanbang Biopharmaceuticals Co. Ltd. this year, we will have two compounds simultaneously in clinical trials. This highlights the strength of Sirona’s platform technology in creating novel compounds for both therapeutic and cosmetic indications with excellent potential for full commercialization.”
About Dr. Zoe Draelos
Dr. Zoe Draelos is a clinical and research dermatologist based in High Point, North Carolina. Dr. Draelos, supported by a team of highly skilled scientists, is the head of the Dermatology Consulting Services (DCS) research organization, aimed at facilitating research, consulting and communication services to the pharmaceutical and cosmetic industries. The clinical trial center runs assessments on different skin, hair and nail conditions, such as acne, psoriasis, hair loss and aging.
With over thirty years of experience, Dr. Draelos has been recognized many times over the years for her cutting-edge research, including the lifetime achievement award from Health Beauty America and the Society of Cosmetic Chemists. A pioneer in the field of cosmetic dermatology, Dr. Draelos continues to work with lead cosmetic and pharmaceutical companies as well as furthering her own research in the dermatology space.
Dr. Draelos was a past vice-president of the American Academy of Dermatology and is a Consulting Professor of Dermatology at Duke University. She has authored over 300 articles, 8 books and has shared her expertise across different media.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Engages Consultant for Japanese Market Penetration
Momentum Public Relations
Press Release: October 17, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to announce that it has engaged Mr. Sven Harpering, a Tokyo-based consultant, with the help of its strategic advisory firm, PRC Partners (“PRC”) to fast-track negotiations in Japan.
Sven Harpering is a recognized Japanese business expert, with a Masters in East-Asian Studies. He has 14 years of business experience in Germany and 10 years in Japan, where he built a strong track record working in top management positions within various businesses.
With a deep insight of Japanese business culture and a high degree of fluency in Japanese, he is currently acting as a door-opener, consultant, intermediary and interpreter for a complex and demanding cross-section of businesses including; medical instruments, cosmetics, food and food-supplements.
The Company has appointed Mr. Harpering to build and negotiate licensing agreements for Sirona’s lead skin-lightening active TFC-1067 as well as its anti-wrinkle compound LIP-01, exclusively in Japan. Mr. Harpering will be working as a full time consultant for Sirona.
Asia continues to be the fastest growing market for skin-lightening, with high consumer purchasing power and a large demand for safe, effective products that are hydroquinone-free. Japan, specifically, is the largest skin-lightening market in the world, accounting for approximately 70% of the global market revenue, or 14 billion USD.
Sirona recognized the difficulty of penetrating the valuable Japanese market and elected to bring Mr. Harpering on board to capitalize on his extensive expertise in the market and his experience negotiating deals with government officials. Because he is based in Japan and speaks fluent Japanese, this will enable and expedite discussions with leading Japanese cosmetic companies.
“We are pleased to have Mr. Harpering representing Sirona in Japan and taking the lead in finding the right partners for TFC-1067 and LIP-01,” said Dr. Howard Verrico, CEO of Sirona Biochem. “It is essential we have an expert located in Japan who is familiar with the local business customs, can act quickly and has previously achieved success in negotiations in Japan. We believe this is the most cost-effective way to introduce Sirona to the large cosmetic companies in Japan and develop partnerships.”
Sirona remains focused on securing licensing agreements for TFC-1067 in North America and China. As discussions move forward, expanding Sirona’s market reach will ensure greater success for TFC-1067. With the assistance of PRC and the consultants in Japan and China, the Company believes it will be successful in licensing TFC-1067 in Asia, and North America.
About PRC Partners
PRC Partners is a Hong Kong-based corporate development consulting firm with a strong focus on China and Japan. The company assists Canadian public companies in tapping investment funds and high-net-worth individuals in Asia.
PRC Partners has a specific focus on the discovery of undervalued and promising growth companies and serves these companies by increasing visibility and accessing capital through an experienced network of investors.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona Biochem Announces Close of Financing and Extension of Convertible Notes
Momentum Public Relations
Press Release: October 17, 2018
Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (the “Company”) announced that it has closed a private placement (subject to TSX.V approval) in the amount of 7,095,100 units at $0.10 per unit for total gross proceeds of $709,510. Each unit consists of one common share and one transferable share purchase warrant. Each whole warrant is exercisable into one additional common share of the Company for a period of three years, from the date of issue, at a price of $0.18 per share.
The Company paid a total of $9,532 in finder’s fees in connection with the placement.
“We are very pleased that we have ongoing support from our existing shareholders as well as interest from new parties,” said Howard Verrico, CEO. “The funds will go toward the upcoming clinical trial, international partnering activities, paying off a portion of existing convertible notes, as well as general operating expenses.”
All securities issued under the placement are subject to statutory hold periods expiring on February 16, 2019.
The Company also announced that it extended $443,600 of the $665,360 convertible notes that matured August 31, 2018. Each Note will be extended for a 12 month term, convertible at the option of the holder into one common share of the company at a conversion price of $0.14 per share.
The Notes will bear interest at the rate of 12% per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period. The Notes are unsecured and transferable, subject to resale restrictions under applicable securities laws and TSX Venture Exchange requirements.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona Biochem to Present at the 2018 Arctic Circle Assembly
Momentum Public Relations
Press Release: October 11, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (the “Company”) announced today that Chief Scientific Officer, Dr. Geraldine Deliencourt-Godefroy will attend and present at the Arctic Circle Assembly. This conference will take place October 19th – 21st at the Harpa Conference Center in Reykjavik, Iceland.
The Arctic Circle Assembly is the largest international gathering on the future of the Arctic. As described by the organizers, this annual event invites attendees from 60 countries, ranging from heads of states and governments, ministers, members of parliament, officials, experts, scientists, entrepreneurs, business leaders, indigenous representatives, environmentalists, students, activists and others from the growing international community of partners and participants interested in the future of the Arctic. The Assembly covers a wide variety of topics designed in collaboration with partner organizations.
Dr. Deliencourt-Godefroy will be presenting in the Science and Traditional Knowledge Program. She’ll be discussing her work on glycoproteins based on arctic fish, a project she has been passionate about since her career began. In her post-doctoral research, Dr. Deliencourt-Godefroy was inspired by the naturally occurring antifreeze glycoproteins in the bloodstream of some fish that allow them to survive sub-zero temperatures. She has since developed a novel, patented family of compounds with a unique ability to resist stress, that are suitable for numerous commercial applications.
For over fifteen years, Dr. Deliencourt-Godefroy has continued to receive recognition for her innovative research and development within Europe, especially by the French Government. Prior to the Arctic Circle Assembly, Dr. Deliencourt-Godefroy will be attending Cosmetic 360 in Paris, France. At this global cosmetic trade fair, Sirona will be attending pre-arranged meetings as well as continuing to build networks with top industry representatives in cosmetics.
About the Arctic Circle Assembly
Established in 2013, the Arctic Circle Assembly is organized by the Arctic Circle, a non-profit organization creating a dialogue to discuss the future of the Arctic. Attended by over 2000 people from 60 countries each year, political figures, environmental experts, business leaders and scientists gather to raise global awareness of this region.
Alongside the assembly, the Arctic Circle organizes smaller forums around the world, to focus on specific environments and facilitate further discussion. For more information, visit: http://www.arcticcircle.org/
About Cosmetic 360
Cosmetic 360 is an innovative-centered trade fair for the cosmetic industry. The conference brings together professionals and industry representatives from all over the world. All facets of the cosmetic industry are represented at the conference including raw materials, formulation, packaging, testing and analysis, finished products, and distribution. More information on the conference can be found at https://www.cosmetic-360.com/en/
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Medical Marijuana, News Home, Sirona Biochem
Sirona Biochem CEO’s Report on Progress
Momentum Public Relations
Press Release: September 28, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) provided a shareholder corporate update today from the Company’s CEO, Dr. Howard J Verrico.
Dear Shareholders,
As the summer comes to a close and we enter the final months of 2018, I am eager to share the progress of Sirona’s recent clinical development and partnering activities. We sincerely apologize for the lack of communication recently, as we had been quite busy internally pivoting our strategy. However, we are now in a position to provide a comprehensive update. Sirona’s current strategy is based on a three-pronged attack, which I will explain in detail below, to ensure success in maximizing the value of our skin-lightener TFC-1067.
Clinical Trial Development
As mentioned in our most recent news release, Sirona and its subsidiary laboratory TFChem are nearing completion of the necessary requirements in developing TFC-1067 for a proof of concept, human clinical trial. Through work with a toxicologist and extensive safety studies, a formulation of Sirona’s lead skin lightener has been prepared. The Proof of Concept Clinical Trial will begin late October at a U.S. based clinic. The trial, performed by a lead dermatologist who has worked with many of the top tier pharmaceutical and biotechnology companies world-wide, will take approximately 12 weeks.
North America Strategy
Many Sirona shareholders were aware of the late stage negotiations taking place with a large North American company to license TFC-1067. Even though term sheets had been exchanged, a sudden change in focus by the potential partner company alongside a large internal reorganization has delayed talks. While interest does remain, we made the decision months ago to expand the search for new potential partners in North America. Of the several interested cosmetic companies, one company specifically has invested significant time and resources to evaluate TFC-1067. Accordingly, we are pleased with the progress to date and foresee licensing discussions advancing.
Moreover, with the clinical trial beginning soon, many lead cosmetic companies we have previously spoken to are anticipating the results and will be eager to continue moving forward at that point.
Asia Strategy
While we continue to anticipate a North American licensing deal, Asia accounts for approximately 90% of the global skin-lightening market and continues to grow rapidly. Many North American companies have difficulty penetrating the Asian markets, resulting in lack of sales channels. We believe that working with leading cosmetic companies within Asia, where a majority of sales occur, is critical to entering this market. Previously, Sirona has attempted to navigate the Asian cosmetic market, but the different business practices and relevant contacts necessary, proved to be obstacles. However, Sirona’s strategic advisors PRC Partners Limited (PRC), out of Hong Kong, with their extensive presence and experience in Asia, have helped Sirona over the last five months, specifically in China.
PRC has set up several meetings with major cosmetic companies in the People’s Republic of China. Chief Scientific Officer, Dr. Géraldine Deliencourt-Godefroy, and I have made several trips to China and we are working on several deal options – either working with one major brand to develop TFC-1067 or licensing it to many players in the market through a material supplier, which would make TFC-1067 an OEM product. We are in discussions with companies regarding options.
Although the focus of these meetings has been on TFC-1067, several of the larger companies are also expressing interest in Sirona’s anti-aging compound, LIP-01. This further confirms the large cosmetic demand by the Asian market for novel products.
Ultimately, we believe that focusing on not only the North American market, but also Asia, as well as independently developing TFC-1067 through a proof of concept clinical trial, will allow Sirona to secure the most value from TFC-1067 on a global scale.
Thank you for your continued patience and support. We hope that this update on Sirona’s strategy makes you as confident as we are in regard to licensing TFC-1067. Most importantly, Sirona plans to continue improving communication and transparency moving forward.
Sincerely,
Dr. Howard Verrico, CEO
About PRC Partners
PRC Partners is a Hong Kong-based corporate development consulting firm with a strong focus on China and Japan. The company assists Canadian public companies in tapping investment funds and high-net-worth individuals in Asia.
PRC Partners has a specific focus on the discovery of undervalued and promising growth companies and serves these companies by increasing visibility and accessing capital through an experienced network of investors.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Receives Positive Safety Data for Lead Skin-Lightener in Preparation for Clinical Trial in the US
Momentum Public Relations
Press Release: September 26, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) is pleased to report further progress regarding the clinical development of its lead skin-lightener, TFC-1067.
In parallel with ongoing partnering discussions, Sirona has completed steps toward the clinical trial for TFC-1067. A toxicologist, from CEHTRA in Paris, was hired to approve Sirona’s compound for clinical use. From the pre-clinical data, the toxicologist established a clinical dose for the compound and further confirmed that it does not degrade into toxic metabolites such as hydroquinone and benzoquinone.
The Company also contracted formulation expert Gael Boutry of Global Beauty Consulting in France to develop a formulation acceptable for clinical use. The formulation (face cream) containing TFC-1067 has already been prepared, packaged and tested in an accelerated stability test to ensure shelf-life.
Over the past two months, safety studies with the formulation have been ongoing at Dermscan, Poland, and continue to provide positive data for TFC-1067. The first study, a human patch test on 10 people, confirmed TFC-1067 as a non-irritant, in contrast to many other skin-lighteners.
In early August, a second clinical trial for the Human Repeat Insult Patch Test (HRIPT) which assesses sensitization on a larger group (110 people) began, in preparation for future efficacy trials. Initial results from the panel show TFC-1067 as a non-sensitizer. With these tests completed, Sirona will begin their proof of efficacy clinical trial in October, at a center in the United States, led by an acclaimed dermatologist.
“The significance of the data that supports the formulated TFC-1067 cream as a non-irritant, non-sensitizer cannot be understated, as many common skin-lighteners, like hydroquinone, resorcinol, and Kojic Acid, have known toxicities at effective doses,” said Dr. Howard Verrico, CEO of Sirona Biochem. “The market has an unmet need with the safety and efficacy problems associated with the currently available skin lighteners and we are confident that TFC-1067 will meet this need. With an inventory of formulated product, we are primed to start the trial in October.”
The planned clinical trial does not prevent negotiations of a definitive agreement in the interim. Advancing the development continues to add value to TFC-1067 and shorten the time to full commercialization. This improves our future potential partners ability to share our confidence in the commercial opportunity we are creating. In parallel, meetings with North American and Asian cosmetic companies continue to move forward.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona Biochem Receives $500,000 USD Milestone Payment from Wanbang Biopharmaceuticals
Momentum Public Relations
Press Release: August 28, 2018
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (Xetra: ZSB) (the “Company”) announced that it has received the $500,000 USD milestone payment from partner Wanbang Biopharmaceuticals Co., Ltd (“Wanbang”) for approval by the China Food and Drug Administration of the Phase I Clinical Trial for Sirona’s SGLT-2 inhibitor. Sirona’s SGLT-2 inhibitor, TFC-039, will continue to be developed for the treatment of Type 2 diabetes. Since the two companies signed a licensing agreement in 2014, Sirona Biochem has secured $1.5 million USD in development milestones from Wanbang.
Shortly after the announcement of the approval, Sirona CEO, Dr. Howard Verrico met with the Wanbang team at the Shanghai Fosun Pharmaceutical Industrial Development Company Limited (“Fosun”) headquarters in Shanghai. The meeting focused on next steps in the development of “Wangeliejin”, the name for TFC-039. Wanbang expressed their full dedication to the SGLT-2 inhibitor project. The team also shared that while Wanbang has primarily focused on developing generic drugs, developing TFC-039 shows a need for such a medication in China and their belief in Sirona’s compound. They have heavily invested time and money into the first phase of testing and are dedicated to continuing through to market. Clinical trials are currently being set up and anticipated to begin as early as October – a milestone achievement for both teams.
“As we move into the second half of 2018, we are pleased with the dedication and progress Fosun has made in developing Sirona’s SGLT-2 inhibitor for the Chinese market. Following our most recent meeting in Shanghai, both teams remain enthused about the project and partnership,” said Dr. Howard Verrico, CEO. “Wanbang’s powerful marketing, distribution and retail channels allows them to maintain a strong position in the diabetes treatment market. We look forward to the continued progress in working towards a treatment for Type-2 diabetes.”
About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals
Wanbang Biopharmaceuticals develops, manufactures and sells drugs with indications for chronic disease treatment including endocrine diseases in China. Founded in 1981, they are presently headquartered in Xuzhou, China and are a subsidiary of Shanghai Fosun Pharmaceutical Co., Ltd. Fosun is a leader in the pharmaceutical industry and regarded as one of the top domestic pharmaceutical companies in China. For more information on Fosun and Wanbang, visit https://www.fosunpharma.com/en/.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, please contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Life Sciences, News Home, Sirona Biochem